Sep 28, 2021 08:14 PM (GMT+8) · EqualOcean
Financial Associated Press, September 28 - imikang announced that in order to concentrate resources on the development of information and data business, the company has completed the equity delivery procedures for the transfer of 100% equity of sangruisi, the business implementation subject in the medical and health field, on September 28, 2020. Since the company's joint-stock subsidiary valuebiotech S.r.l Italian intelligent surgical robot technology research and development company ("VBT") is the investment target in the field of medical and health care, in order to avoid horizontal competition with sangruisi, the company plans to transfer its VBT equity within one year after the completion of equity delivery when stripping sangruisi. The company plans to transfer the 5.27% equity of VBT held by the company to the affiliated legal person sangruisi with RMB 4.0766 million. After the completion of this transaction, the company will no longer hold the equity of VBT, and VBT will no longer be a participating subsidiary of the company.